Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cyclacel Pharmaceuticals ( (CYCC) ) just unveiled an announcement.
On July 7, 2025, Cyclacel Pharmaceuticals announced an amendment to its exchange agreement with FITTERS Diversified Berhad, involving a share exchange transaction. The amendment includes an additional payment of USD $1,000,000 to FITTERS and extends the final date for the transaction to September 30, 2025. This strategic move is subject to approval from both companies’ stockholders and aims to enhance Cyclacel’s market positioning by integrating FITTERS’ subsidiary, Fitters Sdn. Bhd., into its operations.
The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology. The company is advancing a diversified pipeline of novel drug candidates targeting oncology and hematology indications.
Average Trading Volume: 1,629,599
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.61M
Learn more about CYCC stock on TipRanks’ Stock Analysis page.